

## The Multiple Dimensions of Insight in Schizophrenia-Spectrum Disorders

Martino Belvederi Murri<sup>\*,1,2,3</sup> and Mario Amore<sup>1,2</sup>

<sup>1</sup>Psychiatric Clinic, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Science, University of Genoa, Genoa, Italy; <sup>2</sup>Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Ospedale Policlinico San Martino, Genoa, Italy; <sup>3</sup>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

\*To whom correspondence should be addressed; Largo Rosanna Benzi, 10, Genoa 16132, Italy; tel: 39 333 5248720, fax: 39 10 3537669, e-mail: [martino.belvederi@gmail.com](mailto:martino.belvederi@gmail.com)

**The concept of insight is used to indicate the propensity of patients with schizophrenia and other severe mental disorders to recognize their illness and engage in treatment. Thus, insight may have notable consequences for the ill individual: Those who lack insight are at higher risk of nonadherence to treatments, negative clinical outcomes, and worse community functioning. Although insight is an intuitive concept, its essence remains difficult to capture. However, many rating scales are available to aid assessment, both for clinical and research purposes. Insight cannot be reduced to a symptom, a psychological mechanism, or a neuropsychological function. It is likely to have dynamic relationships with all these dimensions and with responses to personal events and contextual factors. In particular, social consequences of mental illness and explanatory models that are alternative to the medical model may fundamentally shape insight and treatment choice. Moreover, the cultural or individual stigmatization of mental illness may turn the acquisition of insight into a painful event and increase the risk of depression. Clinicians need to carefully evaluate and promote insight through a personalized approach to aid patient process of care and personal growth.**

*Key words:* schizophrenia/insight/stigma/depression/adherence/social cognition

### What Is Insight?

In the common language, the term “insight” refers to “*the capacity to gain an accurate and deep understanding of someone or something.*” In the psychiatric jargon, however, the term indicates the “*awareness of a mentally ill person that his/her experiences are not based on external reality.*”<sup>1</sup> In clinical practice, “insight” is used to indicate the ability of an individual to critically elaborate on his/her mental disorder and, by extension, the propensity to

engage in treatment. Generally, the study of insight pertains to individuals having schizophrenia or other psychotic disorders, which are characterized by distorted contact with reality.

Although insight is a fairly intuitive concept to grasp, it eludes a precise definition. Moreover, its definition has undergone profound changes as a result of the integration of different points of view. Traditionally, the lack of insight was variously regarded as an intrinsic symptom of the disorder, a neuropsychological deficit, or a psychological defense.<sup>2</sup> More recently, the impact of social and cultural aspects has been also acknowledged,<sup>3,4</sup> and it has become widely accepted that insight is multi-determined.<sup>5,6</sup> This review aims to provide a concise, nontechnical overview of the concept of insight, its development, as well as its correlates and assessment.

The ongoing debate around insight not only has theoretical implications, it is, first and foremost, of clinical utility. It is estimated that about half of patients having schizophrenia lack insight, but what are the consequences of this lack? The need to improve patient insight is widely agreed upon, but *how* can we achieve this goal?

### Why Is Insight Important?

Insight may influence the outcomes of patients with schizophrenia and other psychoses.<sup>7</sup> With regard to schizophrenia, individuals with lower levels of insight have a poorer prognosis in terms of quality of life, social relationships, work, or vocational outcomes across different countries.<sup>6,8–11</sup> Intuitively this would largely depend on the refusal of treatment that leads to increased likelihood of relapses.<sup>12</sup> However, some patients who deny their illness may nonetheless accept treatment or hospitalization. Conversely, patients with good levels of insight may not adhere to prescriptions for various reasons,<sup>13–15</sup> including the preference for alternative care.<sup>16,17</sup> The link between

insight and adherence to antipsychotics is stronger in the months after discharge and decreases with time. Subsequently, patients may discontinue medications if they experience side effects, engage in illicit drug use, or perceive a decreased risk of relapse, regardless of insight.<sup>18</sup> Nevertheless, insight and positive attitudes toward medications are still important factors that predict adherence to antipsychotics.<sup>18,19</sup> Interestingly, insight may also be involved in the uptake of psychotherapy.<sup>20</sup> Overall, it is necessary but not sufficient to ensure adherence to medications<sup>18,19</sup> and engagement with mental health services.<sup>21</sup>

Another supposed consequence of poor insight is increased aggressive behavior. Research findings on this issue are not entirely consistent.<sup>18,22</sup> Uncertainty may depend not only on difficulties in obtaining reliable information on violent behaviors<sup>22,23</sup> but also on cross-cultural variations in both insight and violence.<sup>24</sup> The link between insight and aggressive behavior seems stronger in forensic populations<sup>12</sup> in the presence of psychopathic traits or severe positive symptoms.<sup>25</sup>

### The Assessment of Insight

Many definitions of insight have been proposed, with varying degrees of complexity.<sup>5</sup> Since the development of the Insight and Treatment Attitude Questionnaire by McEvoy et al,<sup>26</sup> various assessment tools have been proposed accordingly, prompting evidence-based research.<sup>18</sup>

Rating scales are more frequently administered by clinicians than compiled by patients, given that the judgment of the clinician is expected to diverge from that of the patient.<sup>18</sup> Instruments may be mono-

multi-dimensional, meaning they can rate single or multiple dimensions of insight. Table 1 reports a list of commonly used rating scales, drawn from a recent review.<sup>27</sup> Two aspects are covered most frequently: The awareness of having a mental disorder, meaning how convinced a subject is that he/she is ill, and the recognition of treatment need. The most widely used mono-dimensional rating is the G12 item of the Positive and Negative Syndrome Scale (PANSS).<sup>28</sup> This item, however, rates the levels of both insight and *judgment*. Judgment is crucial to clinical practice but not entirely pertinent to insight, making the PANSS G12 item a less specific measure. By contrast, an important ad hoc scale is the Schedule for the Assessment of Insight (SAI).<sup>29</sup> The SAI examines (1) the ability to label certain mental events as pathological, (2) the subject's recognition that he/she has a mental disorder, and (3) acceptance of treatment. A later expanded version also rates the awareness of adverse consequences of the illness, as well as the awareness of 4 symptoms.<sup>30</sup> Like the SAI, the Birchwood Insight Scale<sup>31</sup> encompasses 3 domains of insight but it is one of the few self-administered instruments available. Patients are asked if they endorse 8 statements that pertain to the awareness of the illness, the awareness of treatment need, and the relabeling of symptoms. The Scale to Assess Unawareness of Mental Disorder (SUMD), another widespread assessment tool,<sup>32</sup> includes the following aspects, in addition to those described earlier: (1) distinct ratings for symptom awareness and *attribution* (the recognition of symptoms as part of an illness and the explanations on their nature, respectively), (2) several ratings of insight for individual symptoms, and (3) distinct ratings for insight of current

**Table 1.** Overview of Common Tools for Assessing Insight

Instrument	Domains	No. of Items
PANSS item G12 (lack of judgment and insight)	Unidimensional, but rating is based on (1) nonrecognition of past or present psychiatric illness or symptoms; (2) denial of need for psychiatric hospitalization or treatment; (3) decisions characterized by poor anticipation of consequences, and unrealistic short-term and long-range planning	1
ITAQ	(1) Recognition of mental illness; (2) need for hospitalization; (3) need to take medications	11
SAI, SAI-E	(1) Awareness and relabeling of symptoms; (2) awareness of illness; (3) treatment compliance	8 (original version), 12 (expanded version)
SUMD	(1) Insight into mental disorder; (2) insight into need for treatment; (3) insight into social consequences; (4) insight into presence of symptoms; (5) insight into attribution of symptoms	74
BIS	(1) Awareness of illness; (2) awareness of need for treatment; (3) relabeling of symptoms	8 (self-report)
BCIS	(1) Self-reflectiveness (expression of introspection and willingness to acknowledge fallibility); (2) self-certainty (certainty about beliefs or judgments)	15 (self-report)

*Note:* PANSS, Positive and Negative Syndrome Scale; ITAQ, Insight and Treatment Attitudes Questionnaire; SAI-E, Schedule for the Assessment of Insight, Expanded version; SUMD, Scale to Assess Unawareness of Mental Disorder; BIS, Birchwood Insight Scale; BCIS, Beck Cognitive Insight Schedule. All instruments are intended to rate clinical insight, except for the BCIS which is intended to measure cognitive insight. For a more in-depth description, see the review by Lincoln and colleagues.<sup>18</sup>

and past symptoms.<sup>32</sup> The SUMD prompted a comprehensive assessment of insight, but its length makes it impractical for everyday clinical use.<sup>33</sup> Finally, research has recently seen the formulation of cognitive insight, which is assessed by the Beck Cognitive Insight Scale.<sup>34</sup> Cognitive insight essentially refers to flexibility in thinking, which is deemed to constitute the basis of clinical insight. The lack of cognitive insight implies the inability to put experiences into perspective, overconfidence in judgments, and the inability to correct cognitive distortions with the help of others.<sup>35</sup> Several of these scales have been translated for use in non-English-speaking populations, although precise instructions on how to deal with cultural factors are lacking.<sup>3</sup>

### The Elephant in the Room: Social, Cultural, and Cross-cultural Points of View

Insight and its assessment are irremediably permeated by social and cultural factors. However, lack of insight does not merely depend on insufficient education.<sup>36</sup> Providing patients with notions on mental illness through psychoeducation may increase adherence but does not necessarily improve insight.<sup>37,38</sup> Indeed, the understanding of an illness emerges from a complex mixture of cultural background and personal experiences, beliefs and expectations that are collectively termed “explanatory model.”<sup>3</sup> For instance, in a landmark study explanatory models of schizophrenia held by Western-aculturated patients more often involved medical or psychosocial factors, whereas immigrants relied more frequently on spiritual factors (possession, spells) or traumatic events.<sup>39</sup> Notably, alternative explanations do not necessarily exclude the willingness to engage in treatment<sup>11,16,40</sup> and people (with or without psychosis) have been shown to hold different, contradictory explanatory models simultaneously.<sup>3,11,41</sup>

The evaluation of insight must also weigh the implications of mental diagnoses in the social context. Negative stereotypes of mental disorders, discrimination, and social inequity are still widespread in both high- and low-income countries.<sup>42</sup> Stigmatization leads people to reject diagnoses and refuse treatment, even when they are aware of their symptoms.<sup>13,43,44</sup> Even in times of easy access to information, the lay public remains generally prejudiced against individuals with psychosis, which highlights the need for strategies to reduce stigmatization.<sup>42,45,46</sup>

The cultural background of the clinician is also important in the evaluation, or rather, the “negotiation” of insight with the patient.<sup>39</sup> Several authors contend that modern psychiatry is too heavily rooted in the medical–scientific model<sup>47</sup> and, particularly in the “Western” world,<sup>48</sup> psychiatrists pay insufficient attention to cultural, spiritual, and social factors.<sup>39,43,49</sup> However, it has been argued that clinicians during their everyday clinical work may simply adopt implicit, pragmatic models that shift according to the needs of the particular consultation.<sup>50</sup> To avoid the

risk to underestimate patient insight, its assessment should be based on the individual’s cultural standards rather than on disciplinary notions.<sup>48,51,52</sup> Particular efforts must therefore be made to facilitate communication between patients and clinicians from different cultural backgrounds.<sup>53</sup>

### What Is the Time Course of Insight and Its Relationship With Psychopathology?

Insight should not be considered as a stable feature of the individual. In schizophrenia, insight seems more impaired during the first episode of illness, then improves in midlife, but declines again in older age.<sup>54</sup> Marked variations have also been observed over shorter periods. Several patients acquire insight after the resolution of the acute psychotic phase, possibly as an effect of medications,<sup>55,56</sup> psychosocial interventions,<sup>57</sup> or coping with the consequences of the illness.<sup>11</sup> Of note, improvement in insight is at least partly related to changes in symptom severity.<sup>58</sup>

Several studies have examined the relationship between insight and psychotic symptoms, particularly in schizophrenia.<sup>59</sup> Not surprisingly, this relationship is inverse: Severe symptoms, such as delusions, are accompanied by lack of insight, or the inability to criticize such themes. The same inverse relationship has been found with regard to hallucinations, disorganization, and negative symptoms.<sup>60</sup> However, these associations are, on the whole, *weak*, meaning that other factors play an important role. The only symptom dimension that correlates *positively* (but again, weakly) with insight is depression.<sup>27</sup> This phenomenon has been described as the “insight paradox”: The acquisition of insight should be beneficial to the patient, but *paradoxically* leads to another problem. The insight paradox is often related to “post-psychotic depression,” a phase of recovery when patients develop feelings of shame and sadness as they acquire insight.<sup>61</sup> However, insight may be associated with improved self-esteem in later periods.<sup>9</sup> Again, it may be accompanied by demoralization and hopelessness among older patients with chronic disorders.<sup>62</sup> Finally, the relationship between insight and depression is shaped by external factors, including the tendency to stigmatize mental illness by the patient<sup>62,63</sup> or relatives,<sup>64,65</sup> expectations that treatment will be ineffective, insufficient engagement with mental health services, or low socioeconomic status.<sup>66</sup>

The existence of a link with depression prompts the question of whether good insight may increase the risk of suicide. Study results have been mostly negative, but, again, there may be complex effects due to the course of the illness.<sup>67</sup> Improvements in insight *after treatment* have been associated with a reduced risk of suicide, whereas subsequent reductions may have an opposite effect.<sup>68,69</sup> Because most suicides in schizophrenia occur during the first years of illness, young patients must be carefully monitored for insight, signs of depression—particularly hopelessness<sup>70</sup>—and communications related to suicide.<sup>71</sup> These findings

suggest that the acquisition of insight is a complex and delicate process that depends on individual clinical characteristics, personal history, and environmental circumstances.<sup>37</sup>

### Does Insight Depend on Neurocognitive, Metacognitive, or Social-Cognitive Abilities?

Cognitive abilities have been investigated as constituents of insight. Research suggests that insight is more specifically related to memory and executive functions, rather than to global intelligence. However, the association is of modest strength, suggesting that intact neurocognitive abilities are a precondition for insight, rather than the essence of it.<sup>72</sup>

Insight also seems to be essentially related to higher-order thinking skills, namely metacognition and social-cognition. Although the exact boundaries between these constructs are difficult to define, metacognition traditionally includes the ability to reflect on one's own mental processes and form integrated ideas about the self, whereas social-cognition entails the mental processes underlying social relationships.<sup>6,73,74</sup> The relevance of these dimensions is clear if we consider that insight requires the capacity to shift back and forth from one's own perspective, to form integrated views of oneself and one's mental processes, and to trust and accept help from others.<sup>74</sup> Individuals who display greater metacognitive and social-cognitive abilities are more likely to give meaning to life events, including mental illness, and to construct integrated narrative accounts that form the basis of insight.<sup>74</sup> Consistently, interventions that tackle metacognitive abilities by means of a narrative, meaning-oriented approach have shown promising results in terms of improving awareness.<sup>6,8,75,76</sup>

### Other Points of View: Psychoanalysis, Phenomenology, and Neuroscience

The psychoanalytic literature has formalized the concept of defense mechanisms, which ward off painful emotions stemming from awareness. Primitive defenses, such as denial or projection, are particularly implicated in reality distortion and delusions.<sup>77</sup> As such, lack of insight (ie, denial of the illness) would protect the individual from the painful awareness of being mentally ill. By definition these theories are difficult to test; nonetheless, a few studies have used questionnaires assessing "self-deception" to estimate the tendency to enact denial. In 1 of 2 such studies, greater self-deception was indeed associated with worse levels of insight.<sup>78,79</sup> In other studies, the coping style termed "sealing over" has been seen to characterize the tendency of individuals with low levels of insight to repress the awareness of their psychosis or to regard it as irrelevant.<sup>80</sup>

A radically different account of insight is found in the phenomenological literature. In this view, schizophrenia is characterized by alarming and alienating self-experiences such as an abnormal sense of the body, body ownership

and agency, and a primary disturbance of the *structure of experience* (termed "basic self-world structure").<sup>81</sup> Thus, psychotic experiences are indistinguishable from real ones even in the presence of evident contradictions. Therefore, insight is regarded not as a problem of self-reflection, but rather as a consequence of the altered structure of experiencing.<sup>82</sup>

Finally, research has started to unravel the neurobiological basis of insight. Several brain areas have been found to subserve insight,<sup>83</sup> including the prefrontal and cingulate cortices, temporal and parietal lobes, the hippocampi, and cerebellum.<sup>83,84</sup> In particular, poor insight would emerge from impaired function of self-processing areas.<sup>85</sup> Finally, genetic research is also underway.<sup>86</sup>

### Conclusions

Here, we provide a nontechnical, narrative overview on the nature, importance, and assessment of insight in schizophrenia-spectrum disorders. Insight is a key multidetermined clinical dimension, likely to influence both adherence to treatment and clinical outcomes. Although it eludes simple definitions, insight can be readily assessed with the aid of standardized rating instruments. However, particular attention must be paid to the patient's specific cultural, social, and personal background. Nonmedical explanatory models, social disadvantage, and stigmatization may hinder the recognition of mental disorders and the acceptance of treatment. Insight generally improves as symptoms abate during treatment but may lead to depression, shame, and hopelessness. In such cases, suicidal ideas should be thoroughly investigated.<sup>71</sup> Lack of insight has been traditionally viewed as a symptom, a cognitive deficit, or a defense mechanism, whereas modern accounts tend to point to impairments of metacognitive and social-cognitive abilities. These predisposing factors hinder patients' ability to make sense of their illness in a structured and narrative manner. By contrast, an integrated, culturally sensitive view of insight is paramount to promote awareness and personal growth in patients with severe psychotic disorders.<sup>6,87,88</sup>

### Acknowledgments

The authors would like to thank Prof. Bernard Patrick for the linguistic revision of the article. The authors have declared that there are no conflicts of interest in relation to the subject of this study.

### References

1. Stevenson A, ed. *Oxford Dictionary of English*. Oxford University Press; 2010; doi:10.1093/acref/9780199571123.001.0001
2. Cooke MA, Peters ER, Kuipers E, Kumari V. Disease, deficit or denial? Models of poor insight in psychosis. *Acta Psychiatr Scand*. 2005;112:4–17.

3. Jacob KS. Insight in psychosis: standards, science, ethics and value judgment. *Int J Soc Psychiatry*. 2017;63:345–351.
4. Jacob KS. The assessment of insight across cultures. *Indian J Psychiatry*. 2010;52:373–377.
5. Fulford B (KWM). Insight and delusion: from Jaspers to Kraepelin and back again via Austin. In: Amador XF, David AS, eds. *Insight and Psychosis: Awareness of Illness in Schizophrenia and Related Disorders*. 2nd ed. New York, NY: Oxford University Press; 2004:51–78; doi:10.1093/med/9780198525684.003.0003
6. Lysaker PH, Pattison ML, Leonhardt BL, Phelps S, Vohs JL. Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. *World Psychiatry*. 2018;17:12–23.
7. Drake RJ. Insight into illness: impact on diagnosis and outcome of nonaffective psychosis. *Curr Psychiatry Rep*. 2008;10:210–216.
8. Lysaker PH, Hamm JA, Hasson-Ohayon I, Pattison ML, Leonhardt BL. Promoting recovery from severe mental illness: implications from research on metacognition and meta-cognitive reflection and insight therapy. *World J Psychiatry*. 2018;8:1–11.
9. Klaas HS, Clémence A, Marion-Veyron R, et al. Insight as a social identity process in the evolution of psychosocial functioning in the early phase of psychosis. *Psychol Med*. 2017;47:718–729.
10. Crumlish N, Samalani P, Sefasi A, Kinsella A, O’Callaghan E, Chilale H. Insight, psychopathology and global functioning in schizophrenia in urban Malawi. *Br J Psychiatry*. 2007;191:262–263.
11. Johnson S, Sathyaseelan M, Charles H, Jeyaseelan V, Jacob KS. Insight, psychopathology, explanatory models and outcome of schizophrenia in India: a prospective 5-year cohort study. *BMC Psychiatry*. 2012;12:159.
12. Drake RJ. Insight into illness: impact on diagnosis and outcome of nonaffective psychosis. *Curr Psychiatry Rep*. 2008;10:210–216.
13. Kirmayer LJ, Corin E, Jarvis GE. Inside knowledge: cultural constructions of insight in psychosis. In: Amador XF, David AS, eds. *Insight and Psychosis: Awareness of Illness in Schizophrenia and Related Disorders*. 2nd ed. New York, NY: Oxford University Press; 2004:197–229.
14. Linden M, Godemann F. The differentiation between ‘lack of insight’ and ‘dysfunctional health beliefs’ in schizophrenia. *Psychopathology*. 2007;40:236–241.
15. Moritz S, Favrod J, Andreou C, et al. Beyond the usual suspects: positive attitudes towards positive symptoms is associated with medication noncompliance in psychosis. *Schizophr Bull*. 2013;39:917–922.
16. Asher L, Fekadu A, Hanlon C. Global mental health and schizophrenia. *Curr Opin Psychiatry*. 2018;31:193–199.
17. Chilale HK, Silungwe ND, Gondwe S, Masulani-Mwale C. Clients and carers perception of mental illness and factors that influence help-seeking: where they go first and why. *Int J Soc Psychiatry*. 2017;63:418–425.
18. Lincoln TM, Lüllmann E, Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. *Schizophr Bull*. 2007;33:1324–1342.
19. Sendt KV, Tracy DK, Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. *Psychiatry Res*. 2015;225:14–30.
20. Freeman D, Dunn G, Garety P, et al. Patients’ beliefs about the causes, persistence and control of psychotic experiences predict take-up of effective cognitive behaviour therapy for psychosis. *Psychol Med*. 2013;43:269–277.
21. Kvrđic S, Cavelti M, Beck EM, Rüşch N, Vauth R. Therapeutic alliance in schizophrenia: the role of recovery orientation, self-stigma, and insight. *Psychiatry Res*. 2013;209:15–20.
22. Witt K, van Dorn R, Fazel S. Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. *PLoS One*. 2013;8:e55942.
23. Krakowski MI, Czobor P. The denial of aggression in violent patients with schizophrenia. *Schizophr Res*. 2012;141:228–233.
24. Volavka J, Laska E, Baker S, Meisner M, Czobor P, Krivelevich I. History of violent behaviour and schizophrenia in different cultures. Analyses based on the WHO study on determinants of outcome of severe mental disorders. *Br J Psychiatry*. 1997;171:9–14. <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9328487>
25. Lincoln TM, Hodgins S. Is lack of insight associated with physically aggressive behavior among people with schizophrenia living in the community? *J Nerv Ment Dis*. 2008;196:62–66.
26. McEvoy JP, Apperson LJ, Appelbaum PS, et al. Insight in schizophrenia. Its relationship to acute psychopathology. *J Nerv Ment Dis*. 1989;177:43–47.
27. Belvederi Murri M, Respingo M, Innamorati M, et al. Is good insight associated with depression among patients with schizophrenia? Systematic review and meta-analysis. *Schizophr Res*. 2015;162:234–247.
28. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13:261–276.
29. David AS. Insight and psychosis. *Br J Psychiatry*. 1990;156:798–808.
30. Kemp R, David A. Insight and compliance. In: Blackwell B, ed. *Treatment Compliance and the Treatment Alliance in Serious Mental Illness*. The Netherlands: Harwood Academic Publishers; 1997:61–84.
31. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M. A self-report insight scale for psychosis: reliability, validity and sensitivity to change. *Acta Psychiatr Scand*. 1994;89:62–67.
32. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM. Assessment of insight in psychosis. *Am J Psychiatry*. 1993;150:873–879.
33. Dumas R, Baumstarck K, Michel P, Lançon C, Auquier P, Boyer L. Systematic review reveals heterogeneity in the use of the scale to assess unawareness of mental disorder (SUMD). *Curr Psychiatry Rep*. 2013;15:361.
34. Beck AT, Baruch E, Balter JM, Steer RA, Warman DM. A new instrument for measuring insight: the Beck cognitive insight scale. *Schizophr Res*. 2004;68:319–329.
35. Riggs SE, Grant PM, Perivoliotis D, Beck AT. Assessment of cognitive insight: a qualitative review. *Schizophr Bull*. 2012;38:338–350.
36. Wiffen BD, Rabinowitz J, Lex A, David AS. Correlates, change and “state or trait” properties of insight in schizophrenia. *Schizophr Res*. 2010;122:94–103.
37. Lysaker PH, Vohs J, Hillis JD, et al. Poor insight into schizophrenia: contributing factors, consequences and emerging treatment approaches. *Expert Rev Neurother*. 2013;13:785–793.
38. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. *Schizophr Bull*. 2011;37:21–22.

39. Tranulis C, Corin E, Kirmayer LJ. Insight and psychosis: comparing the perspectives of patient, entourage and clinician. *Int J Soc Psychiatry*. 2008;54:225–241.
40. Berg AO, Barrett EA, Nerhus M, et al. Psychosis: clinical insight and beliefs in immigrants in their first episode. *Early Interv Psychiatry*. 2015;12:185–192.
41. Caqueo-Urizar A, Boyer L, Baumstarck K, Gilman SE. The relationships between patients' and caregivers' beliefs about the causes of schizophrenia and clinical outcomes in Latin American countries. *Psychiatry Res*. 2015;229:440–446.
42. Stuart H. Reducing the stigma of mental illness. *Glob Ment Health (Camb)*. 2016;3:e17.
43. Kim Y. Japanese attitudes towards insight in schizophrenia. In: Amador XF, David AS, (eds). *Insight and Psychosis: Awareness of Illness in Schizophrenia and Related Disorders*. 2nd ed. New York, NY: Oxford University Press; 2004:231–241.
44. Beck EM, Cavelti M, Kvrjic S, Kleim B, Vauth R. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication. *Schizophr Res*. 2011;132:42–49.
45. Mittal D, Sullivan G, Chekuri L, Allee E, Corrigan PW. Empirical studies of self-stigma reduction strategies: a critical review of the literature. *Psychiatr Serv*. 2012;63:974–981.
46. Wood L, Byrne R, Varese F, Morrison AP. Psychosocial interventions for internalised stigma in people with a schizophrenia-spectrum diagnosis: a systematic narrative synthesis and meta-analysis. *Schizophr Res*. 2016;176:291–303.
47. Phillips J. Conceptual models for psychiatry. *Curr Opin Psychiatry*. 2000;13:683–688.
48. Saravanan B, David A, Bhugra D, Prince M, Jacob KS. Insight in people with psychosis: the influence of culture. *Int Rev Psychiatry*. 2005;17:83–87.
49. Saravanan B, Jacob KS, Prince M, Bhugra D, David AS. Culture and insight revisited. *Br J Psychiatry*. 2004;184:107–109.
50. Lazare A. Hidden conceptual models in clinical psychiatry. *N Engl J Med*. 1973;288:345–351.
51. Biswas J, Gangadhar BN, Keshavan M. Cross cultural variations in psychiatrists' perception of mental illness: a tool for teaching culture in psychiatry. *Asian J Psychiatr*. 2016;23:1–7.
52. Uptegrove R, Atulomah O, Brunet K, Chawla R. Cultural and social influences of negative illness appraisals in first-episode psychosis. *Early Interv Psychiatry*. 2013;7:399–406.
53. Bhui K, Aslam RW, Palinski A, et al. Interventions designed to improve therapeutic communications between black and minority ethnic people and professionals working in psychiatric services: a systematic review of the evidence for their effectiveness. *Health Technol Assess*. 2015;19:vii–xxiv, 1.
54. Gerretsen P, Plitman E, Rajji TK, Graff-Guerrero A. The effects of aging on insight into illness in schizophrenia: a review. *Int J Geriatr Psychiatry*. 2014;29:1145–1161.
55. Gerretsen P, Takeuchi H, Ozzoude M, Graff-Guerrero A, Uchida H. Insight into illness and its relationship to illness severity, cognition and estimated antipsychotic dopamine receptor occupancy in schizophrenia: an antipsychotic dose reduction study. *Psychiatry Res*. 2017;251:20–25.
56. Pijnenborg GH, Timmerman ME, Derks EM, Fleischhacker WW, Kahn RS, Aleman A. Differential effects of antipsychotic drugs on insight in first episode schizophrenia: data from the European First-Episode Schizophrenia Trial (EUFEST). *Eur Neuropsychopharmacol*. 2015;25:808–816.
57. Pijnenborg GH, van Donkersgoed RJ, David AS, Aleman A. Changes in insight during treatment for psychotic disorders: a meta-analysis. *Schizophr Res*. 2013;144:109–117.
58. Quee PJ, van der Meer L, Krabbendam L, et al. Insight change in psychosis: relationship with neurocognition, social cognition, clinical symptoms and phase of illness. *Acta Psychiatr Scand*. 2014;129:126–133.
59. Mintz AR, Dobson KS, Romney DM. Insight in schizophrenia: a meta-analysis. *Schizophr Res*. 2003;61:75–88.
60. Xavier RM, Pan W, Dungan JR, Keefe RSE, Vorderstrasse A. Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia. *Schizophr Res*. 2018;193:83–90.
61. Uptegrove R, Ross K, Brunet K, McCollum R, Jones L. Depression in first episode psychosis: the role of subordination and shame. *Psychiatry Res*. 2014;217:177–184.
62. Cavelti M, Kvrjic S, Beck EM, Rüschi N, Vauth R. Self-stigma and its relationship with insight, demoralization, and clinical outcome among people with schizophrenia spectrum disorders. *Compr Psychiatry*. 2012;53:468–479.
63. Lysaker PH, Roe D, Yanos PT. Toward understanding the insight paradox: internalized stigma moderates the association between insight and social functioning, hope, and self-esteem among people with schizophrenia spectrum disorders. *Schizophr Bull*. 2007;33:192–199.
64. Krupchanka D, Katliar M. The role of insight in moderating the association between depressive symptoms in people with schizophrenia and stigma among their nearest relatives: a pilot study. *Schizophr Bull*. 2016;42:600–607.
65. Poole NA, Crabb J, Osei A, Hughes P, Young D. Insight, psychosis, and depression in Africa: a cross-sectional survey from an inpatient unit in Ghana. *Transcult Psychiatry*. 2013;50:433–441.
66. Belvederi Murri M, Amore M, Calcagno P, et al. The "insight paradox" in schizophrenia: magnitude, moderators and mediators of the association between insight and depression. *Schizophr Bull*. 2016;42:1225–1233.
67. López-Moriñigo JD, Ramos-Ríos R, David AS, Dutta R. Insight in schizophrenia and risk of suicide: a systematic update. *Compr Psychiatry*. 2012;53:313–322.
68. Barrett EA, Mork E, Færden A, et al. The development of insight and its relationship with suicidality over one year follow-up in patients with first episode psychosis. *Schizophr Res*. 2015;162:97–102.
69. Bourgeois M, Swendsen J, Young F, et al.; InterSePT Study Group. Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial. *Am J Psychiatry*. 2004;161:1494–1496.
70. Melle I, Barrett EA. Insight and suicidal behavior in first-episode schizophrenia. *Expert Rev Neurother*. 2012;12:353–359.
71. Pompili M, Belvederi Murri M, Patti S, et al. The communication of suicidal intentions: a meta-analysis. *Psychol Med*. 2016;46:2239–2253.
72. Nair A, Palmer EC, Aleman A, David AS. Relationship between cognition, clinical and cognitive insight in psychotic disorders: a review and meta-analysis. *Schizophr Res*. 2014;152:191–200.
73. Lysaker PH, Vohs J, Minor KS, et al. Metacognitive deficits in schizophrenia: presence and associations with psychosocial outcomes. *J Nerv Ment Dis*. 2015;203:530–536.
74. Vohs JL, George S, Leonhardt BL, Lysaker PH. An integrative model of the impairments in insight in schizophrenia: emerging research on causal factors and treatments. *Expert Rev Neurother*. 2016;16:1193–1204.

75. Moritz S, Mahlke CI, Westermann S, et al. Embracing psychosis: a cognitive insight intervention improves personal narratives and meaning-making in patients with schizophrenia. *Schizophr Bull.* 2018;44:307–316.
76. Lam KCK, Ho CPS, Wa JC, et al. Metacognitive training (MCT) for schizophrenia improves cognitive insight: a randomized controlled trial in a Chinese sample with schizophrenia spectrum disorders. *Behav Res Ther.* 2015;64:38–42.
77. Vaillant GE. Involuntary coping mechanisms: a psychodynamic perspective. *Dialogues Clin Neurosci.* 2011;13:366–370.
78. Moore O, Cassidy E, Carr A, O’Callaghan E. Unawareness of illness and its relationship with depression and self-deception in schizophrenia. *Eur Psychiatry.* 1999;14:264–269.
79. Kruck CL, Flashman LA, Roth RM, Koven NS, McAllister TW, Saykin AJ. Lack of relationship between psychological denial and unawareness of illness in schizophrenia-spectrum disorders. *Psychiatry Res.* 2009;169:33–38.
80. McGlashan TH, Docherty JP, Siris S. Integrative and sealing-over recoveries from schizophrenia: distinguishing case studies. *Psychiatry.* 1976;39:325–338.
81. Hur JW, Kwon JS, Lee TY, Park S. The crisis of minimal self-awareness in schizophrenia: a meta-analytic review. *Schizophr Res.* 2014;152:58–64.
82. Henriksen MG, Parnas J. Self-disorders and schizophrenia: a phenomenological reappraisal of poor insight and noncompliance. *Schizophr Bull.* 2014;40:542–547.
83. Xavier RM, Vorderstrasse A. Neurobiological basis of insight in schizophrenia: a systematic review. *Nurs Res.* 2016;65:224–237.
84. Sapara A, Ffytche DH, Birchwood M, et al. Preservation and compensation: the functional neuroanatomy of insight and working memory in schizophrenia. *Schizophr Res.* 2014;152:201–209.
85. Ćurčić-Blake B, van der Meer L, Pijnenborg GH, David AS, Aleman A. Insight and psychosis: functional and anatomical brain connectivity and self-reflection in Schizophrenia. *Hum Brain Mapp.* 2015;36:4859–4868.
86. Xavier RM, Vorderstrasse A, Keefe RSE, Dungan JR. Genetic correlates of insight in schizophrenia. *Schizophr Res.* 2018;195:290–297.
87. Vohs JL, Leonhardt BL, James AV, et al. Metacognitive reflection and insight therapy for early psychosis: a preliminary study of a novel integrative psychotherapy. *Schizophr Res.* 2018;195:428–433.
88. Jørgensen R, Licht RW, Lysaker PH, et al. Effects on cognitive and clinical insight with the use of guided self-determination in outpatients with schizophrenia: a randomized open trial. *Eur Psychiatry.* 2015;30:655–663.